Alex Therapeutics and Navamedic Partner For Companion App for Parkinson’s Treatment

Image credit: stock.adobe.com

More and more, pharmaceutical companies are turning to smart phones to enhance treatments.

Alex Therapeutics announced that it has partnered with Navamedic to develop an app to be used alongside prescription Parkinson’s disease treatment Flexilev.¹ According to a press release, the app will provide users with medication management support and will be designed specifically for people living with Parkinson’s disease.

Parkinson’s impacts both motor functions and cognitive ability. The app will provide patients struggling with these impacts of the disease with features such as reminders and treatment logs.

Alex Therapeutics will combine its digital health expertise with Navamedic’s drug knowledge.

In a press release, Alex Therapeutics founder and CEO John Drakenberg said, "We are proud to partner with Navamedic to bring this tailored solution to the Parkinson's community. Our goal is to empower patients to manage their treatments effectively, for better symptom relief and improved quality of life."

Kathrine Gamborg Andreassen, CEO of Navamedic, added, “We are excited to collaborate with Alex Therapeutics to enhance the lives of Parkinson's patients through the companion app. This partnership not only reflects our commitment to making the treatment more accessible and manageable, but also underscores our dedication to easing the burden that patients face in their day-to-day care."

This is Alex Therapeutics’ latest collaboration. In January of this year, the company partnered with Vicore Pharma to develop a mobile app designed to provide treatment for anxiety based on cognitive behavioral therapy.²

In a press release issued at the time, Drakenberg said, “It's very rewarding to see that our tailored, evidence-based CBT intervention in Almee had a clinically meaningful impact for PF patients suffering from anxiety. The results of the COMPANION study demonstrate what can be achieved through a great partnership like the one we've had with Vicore Pharma. It's really groundbreaking, with so few digital therapies having published such positive randomized controlled trial results to date. We've shown how partnering to design and develop engaging, user-friendly, patient-facing apps is the best way to work together to change behavior and improve patient outcomes.”

In the same press release, Vicore’s CEO Ahmed Mousa added, “We're so pleased to see these positive results in the COMPANION pivotal study and believe that Almee can play a key role in combination with molecular therapies to address individuals suffering from pulmonary fibrosis in a holistic way."

Dr. Maureen Horton, professor of pulmonary and critical care medicine at Johns Hopkins University School of Medicine (retired) and principal investigator on the COMPANION study, also said, “It is very encouraging to see a digital CBT demonstrating a clear clinical benefit for individuals suffering from the mental health burden that accompanies pulmonary fibrosis. Providing behavior-modifying tools that enhance quality of life represents a new addition to a comprehensive treatment approach for patients suffering from this devastating disease."

Source

1. Alex Therapeutics Has Signed an Exclusive Agreement with Navamedic for the Development of a Companion App to Aid in the Treatment of Parkinson’s Disease. Alex Therapeutics. September 12, 2024. https://www.prnewswire.com/news-releases/alex-therapeutics-has-signed-an-exclusive-agreement-with-navamedic-for-the-development-of-a-companion-app-to-aid-in-the-treatment-of-parkinsons-disease-302246418.html
2. Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety. Alex Therapeutics. January 4, 2024. Accessed September 12, 2024. https://www.prnewswire.com/news-releases/alex-therapeutics-reports-positive-results-from-the-randomized-controlled-trial-of-its-digital-therapy-for-anxiety-302026100.html